Primary study endpoints.

The numbers of primary endpoints are presented as reported in the publications.a. One publication did not define any endpoint as the primary one, and six named more than one primary endpoint. Therefore, the number of endpoints differs from the number of included studies.b. Included median overall survival (time) and survival rates.c. Included combined surrogate measures such as PFS.d. Included best overall response, clinical response, objective response rate, and (tumor) response rate.e. Included early disease progression rate, time to second progression, time to tumor progression, time to treatment failure, and tumor control rate after 6 months.f. Included proportion of patients with histologically confirmed malignant glioma on central neuropathological review without residual contrast-enhancing tumor on postoperative MRI, time to CNS metastases (time from randomization to the radiological occurrence of CNS failure), and impact of the addition of GM-CSF to the MPS160/ISA-51 vaccine (maximum change in the frequency of peptide-specific cytotoxic T lymphocytes in peripheral blood from pre-treatment levels (tetramer analysis).AA: anaplastic astrocytoma, CNS: central nervous system, DFS: disease-free survival, GM-CSF: granulocyte macrophage colony-stimulating factor, MRI: magnetic resonance imaging, PFS: progression-free survival, PROs: patient reported outcomes.Primary study endpoints.